ReviewViruses2019
Human Antimicrobial Peptides as Therapeutics for Viral Infections.
Review in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 222 citations in OpenAlex.
- Effects of Vitamin D Supplementation and Baseline Vitamin D Status on Acute Respiratory Infections and Cathelicidin: A Randomized Controlled Trial.Open forum infectious diseases · 2024Trial
- Role of antimicrobial peptide-based biomaterials in respiratory tract infections control.BMC microbiology · 2026Review
- Antimicrobial Resistance: A Bibliometric Review of Patient Health, Mechanisms, and Therapeutic Strategies.Pathogens (Basel, Switzerland) · 2026Review
- Rosacea scleritis and sclero-uveitis; under recognised and over treated.Journal of ophthalmic inflammation and infection · 2026Review
- Phage Display-Derived Peptides Have Neutralizing Activities Against Biofilm Formation byPharmaceuticals (Basel, Switzerland) · 2026Article
- Leveraging Different Distance Functions to Predict Antiviral Peptides with Geometric Deep Learning from ESMFold-Predicted Tertiary Structures.Antibiotics (Basel, Switzerland) · 2026Article
- Identification of Novel TAT-I24-Related Peptides with Antiviral Activities.International journal of molecular sciences · 2025Article
- Machine Learning-Identified Potent Antimicrobial Peptides Against Multidrug-Resistant Bacteria and Skin Infections.Antibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial Peptides Against Arboviruses: Mechanisms, Challenges, and Future Directions.Probiotics and antimicrobial proteins · 2025Review
- RNase 7 and Th cytokines synergistically increase the secretion of interleukin-6 from keratinocytes.Scientific reports · 2025Article
- Design, Synthesis, and Biological Evaluation of New Analogs of Aurein 1.2 Containing Non-Proteinogenic Amino Acids.Molecules (Basel, Switzerland) · 2025Article
- The Contribution of Human Antimicrobial Peptides to Fungi.International journal of molecular sciences · 2025Review
- Advances in antiviral strategies targeting mosquito-borne viruses: cellular, viral, and immune-related approaches.Virology journal · 2025Review
- Revisiting the potential of natural antimicrobial peptides against emerging respiratory viral disease: a review.3 Biotech · 2025Review
- Characterization of Novel Plantaricin-Derived Antiviral Peptides Against Flaviviruses.International journal of molecular sciences · 2025Article
- Article
- Progress in the classification, optimization, activity, and application of antimicrobial peptides.Frontiers in microbiology · 2025Review
- Antimicrobial peptides: natural templates for next-generation therapeutics against antimicrobial resistance.Frontiers in cellular and infection microbiology · 2025Review
- Article
- Enhancing Antimicrobial Peptide Activity through Modifications of Charge, Hydrophobicity, and Structure.International journal of molecular sciences · 2024Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Successful in vivo infection following pathogen entry requires the evasion and subversion of multiple immunological barriers. Antimicrobial peptides (AMPs) are one of the first immune pathways upregulated during infection by multiple pathogens, in multiple organs in vivo. In humans, there are many classes of AMPs exhibiting broad antimicrobial activities, with defensins and the human cathelicidin LL-37 being the best studied examples. Whereas historically the efficacy and therapeutic potential of AMPs against bacterial infection has been the primary focus of research, recent studies have begun to elucidate the antiviral properties of AMPs as well as their role in regulation of inflammation and chemoattraction. AMPs as therapeutic tools seem especially promising against emerging infectious viral pathogens for which no approved vaccines or treatments are currently available, such as dengue virus (DENV) and Zika virus (ZIKV). In this review, we summarize recent studies elucidating the efficacy and diverse mechanisms of action of various classes of AMPs against multiple viral pathogens, as well as the potential use of human AMPs in novel antiviral therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.